LifeTime and improving European healthcare through cell-based interceptive medicine

LifeTime and improving European healthcare through cell-based interceptive medicine

Rajewsky, Nikolaus (Max-Delbrück-Center for Molecular Medicine and Charité Universitätsmedizin Berlin; Charité Universittsmedizin Berlin; Berlin Institute of Health (BIH))
Almouzni, Geneviève (Institut Curie)
Gorski, Stanislaw A. (Max-Delbrück-Center for Molecular Medicine and Charité Universitätsmedizin Berlin)
Aerts, Stein (VIB; Katholieke Universiteit Leuven)
Amit, Ido (Weizmann Institute of Science)
Bertero, Michela G. (Barcelona Institute of Science and Technology (BIST))
Bock, Christoph (Austrian Academy of Sciences; Medical University of Vienna)
Bredenoord, Annelien L. (University Medical Center Utrecht)
Cavalli, Giacomo (Université Montpellier II)
van de Poel, I.R. (TU Delft Values Technology and Innovation)
al., et. (External organisation)

Values Technology and Innovation

2020

Here we describe the LifeTime Initiative, which aims to track, understand and target human cells during the onset and progression of complex diseases, and to analyse their response to therapy at single-cell resolution. This mission will be implemented through the development, integration and application of single-cell multi-omics and imaging, artificial intelligence and patient-derived experimental disease models during the progression from health to disease. The analysis of large molecular and clinical datasets will identify molecular mechanisms, create predictive computational models of disease progression, and reveal new drug targets and therapies. The timely detection and interception of disease embedded in an ethical and patient-centred vision will be achieved through interactions across academia, hospitals, patient associations, health data management systems and industry. The application of this strategy to key medical challenges in cancer, neurological and neuropsychiatric disorders, and infectious, chronic inflammatory and cardiovascular diseases at the single-cell level will usher in cell-based interceptive medicine in Europe over the next decade.

http://resolver.tudelft.nl/uuid:d4f11791-fcdd-455c-8f0e-aad81fdf3c18

https://doi.org/10.1038/s41586-020-2715-9

0028-0836

Nature: international weekly journal of science, 587 (7834), 377-386

Institutional Repository

journal article

© 2020 Nikolaus Rajewsky, Geneviève Almouzni, Stanislaw A. Gorski, Stein Aerts, Ido Amit, Michela G. Bertero, Christoph Bock, Annelien L. Bredenoord, Giacomo Cavalli, I.R. van de Poel, et. al.